• +1 700 888 1234

  • Effingerstrasse 40 3008 Bern Switzerland

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]

Five new members join the Lung Cancer Europe (LuCE) network

We’re delighted to welcome five new member organisations to our growing Lung Cancer Europe (LuCE) network. These organisations and their […]

New LuCE Board elected at AGM 2024 in Zagreb

We are delighted to announce the new Board of Lung Cancer Europe (LuCE) elected at our AGM in Zagreb last […]